Neuberger Berman Group LLC Cuts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Neuberger Berman Group LLC cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 65,038 shares of the company’s stock after selling 2,106 shares during the period. Neuberger Berman Group LLC’s holdings in Omnicell were worth $2,447,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in OMCL. Covestor Ltd raised its stake in Omnicell by 65.6% in the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after buying an additional 537 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Omnicell in the 3rd quarter valued at about $62,000. Neo Ivy Capital Management acquired a new stake in shares of Omnicell during the 3rd quarter worth about $78,000. Allspring Global Investments Holdings LLC lifted its stake in Omnicell by 110.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock worth $153,000 after purchasing an additional 1,777 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in Omnicell in the third quarter valued at approximately $200,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Up 2.9 %

Shares of Omnicell stock opened at $32.63 on Monday. The firm’s fifty day simple moving average is $28.77 and its 200-day simple moving average is $31.26. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48. Omnicell, Inc. has a 12 month low of $25.69 and a 12 month high of $77.14.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The company had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. As a group, analysts anticipate that Omnicell, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OMCL. Benchmark reissued a “buy” rating and set a $38.00 price objective on shares of Omnicell in a report on Tuesday, April 30th. Wells Fargo & Company cut their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $42.20.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.